Compare Pfizer with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs DIVIS LABORATORIES - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER DIVIS LABORATORIES PFIZER/
DIVIS LABORATORIES
 
P/E (TTM) x 48.7 58.0 83.9% View Chart
P/BV x 8.1 15.5 52.1% View Chart
Dividend Yield % 0.4 0.4 107.3%  

Financials

 PFIZER   DIVIS LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-19
DIVIS LABORATORIES
Mar-19
PFIZER/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,8401,639 234.2%   
Low Rs2,0801,115 186.5%   
Sales per share (Unadj.) Rs455.0186.3 244.2%  
Earnings per share (Unadj.) Rs93.851.0 184.0%  
Cash flow per share (Unadj.) Rs109.457.3 190.8%  
Dividends per share (Unadj.) Rs22.5016.00 140.6%  
Dividend yield (eoy) %0.81.2 65.4%  
Book value per share (Unadj.) Rs658.2261.8 251.4%  
Shares outstanding (eoy) m45.75265.47 17.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.57.4 88.0%   
Avg P/E ratio x31.627.0 116.8%  
P/CF ratio (eoy) x27.124.0 112.6%  
Price / Book Value ratio x4.55.3 85.5%  
Dividend payout %24.031.4 76.4%   
Avg Mkt Cap Rs m135,420365,592 37.0%   
No. of employees `0002.611.8 22.2%   
Total wages/salary Rs m3,2385,423 59.7%   
Avg. sales/employee Rs Th7,911.44,175.1 189.5%   
Avg. wages/employee Rs Th1,230.9457.7 268.9%   
Avg. net profit/employee Rs Th1,630.71,141.8 142.8%   
INCOME DATA
Net Sales Rs m20,81549,463 42.1%  
Other income Rs m1,6741,556 107.6%   
Total revenues Rs m22,48951,019 44.1%   
Gross profit Rs m5,71218,718 30.5%  
Depreciation Rs m7141,689 42.3%   
Interest Rs m7335 208.3%   
Profit before tax Rs m6,59918,551 35.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,3095,023 46.0%   
Profit after tax Rs m4,29113,527 31.7%  
Gross profit margin %27.437.8 72.5%  
Effective tax rate %35.027.1 129.2%   
Net profit margin %20.627.3 75.4%  
BALANCE SHEET DATA
Current assets Rs m27,16746,501 58.4%   
Current liabilities Rs m8,9178,468 105.3%   
Net working cap to sales %87.776.9 114.0%  
Current ratio x3.05.5 55.5%  
Inventory Days Days68131 51.8%  
Debtors Days Days3086 35.1%  
Net fixed assets Rs m8,86225,797 34.4%   
Share capital Rs m458531 86.2%   
"Free" reserves Rs m29,65668,962 43.0%   
Net worth Rs m30,11369,493 43.3%   
Long term debt Rs m250-   
Total assets Rs m39,40080,383 49.0%  
Interest coverage x91.5531.0 17.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 85.9%   
Return on assets %11.116.9 65.6%  
Return on equity %14.219.5 73.2%  
Return on capital %22.126.7 82.8%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m42841,238 1.0%   
Fx outflow Rs m78612,405 6.3%   
Net fx Rs m-35828,833 -1.2%   
CASH FLOW
From Operations Rs m9789,543 10.2%  
From Investments Rs m351-6,854 -5.1%  
From Financial Activity Rs m-1,099-2,459 44.7%  
Net Cashflow Rs m231230 100.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 4.9 19.0 25.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.2 137.8%  
Shareholders   85,207 31,796 268.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  FDC  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Maruti Suzuki's Production in April, IDBI Bank's Strategic Divestment, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended higher yesterday. Benchmark indices witnessed buying tracking positive cues from global peers.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


May 6, 2021 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS